Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products Q&A FDA
The FDA's new guidance clarifies reporting requirements and risks for postapproval changes in biosimilars. PCS supports manufacturers in meeting GMP standards, focusing on quality, safety, and alignment with global re...
Jaap Koster
CEO / Senior GxP Consultant